Fig. 6: PARP1 expression and prognosis in cervical cancer patients.

a Relative PARP1 mRNA expression was evaluated by RT-qPCR and samples were normalized to B2M. The relative expression of PARP1 was calculated with the ΔΔCt method, using the mean ΔCt of all samples as a reference sample (S = 15, R = 13). Statistical significances have been evaluated through an unpaired t-test. *P < 0.05 respect to sensitive patients. b Gene expression analysis of PARP1 using GEPIA (gene expression profiling interactive analysis) database (http://gepia.cancer-pku.cn/) based on the TCGA and GTEx database. Box plots represent the gene expression level in terms of log2 (TPM + 1) in the tumor (CESC cervical squamous cell carcinoma and endocervical adenocarcinoma, red, n = 306) and normal (gray, n = 13) samples, respectively.*P < 0.05. c, d Kaplan–Meier survival curves for the probability of PFS (progression-free survival) and OS (overall survival) in TGCA-CESC patients cohort selected for locally advanced cervical cancer (LACC, c n = 147) and for LACC and radiation therapy (d n = 87). PARP1 expression values were converted into discrete variables by dividing the available population cohorts into “high PARP1” and “low PARP1” using the 25th percentile as cutoff: c PARP1 Cutoff = 3906,42; d PARP1 Cutoff = 3837,37. P value in the plot represents the result of the log-rank test.